Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 8 Neoplasms 6 Triple Negative Breast Neoplasms 4 Lung Neoplasms 4 Endometrial Neoplasms 4 Ovarian Neoplasms 3 Neoplasm Metastasis 3 Breast Neoplasms 3 Small Cell Lung Carcinoma 2 Melanoma 2 Carcinosarcoma 2 Bile Duct Neoplasms 2 Advanced Solid Tumours 2 Uterine Cervical Neoplasms 1 Thoracic Neoplasms 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumour Refractory to Conventional Treatment 1 Salivary Gland Neoplasms 1 SCLC 1 Respiratory Tract Neoplasms 1 Respiratory Tract Diseases 1 Prostatic Neoplasms 1 Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma 1 Pancreatic Neoplasms 1 Osteosarcoma 1 Non Small Cell Lung Cancer NSCLC 1 Neoplasms by Site 1 Myelodysplastic Syndromes 1 Lymphoma, Non-Hodgkin 1

Interventions

Ifosfamide 30 Methotrexate 29 Doxorubicin 26 Cyclophosphamide 24 Cisplatin 22 Filgrastim 18 Etoposide 17 Gemcitabine 16 Leucovorin 14 Magnetic Resonance Spectroscopy 11 Temozolomide 10 Specimen Handling 10 cabozantinib 9 apatinib 9 X-Rays 9 Carboplatin 9 fludarabine 8 Radiotherapy 8 Nivolumab 8 Neoadjuvant Therapy 8 Irinotecan 8 Granulocyte Colony-Stimulating Factor 8 Drug Therapy 8 Docetaxel 8 Zoledronic Acid 7 Vincristine 7 Sirolimus 7 Phantoms, Imaging 7 Biopsy 7 mifamurtide 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Osteosarcoma × ceralasertib × Clear all

NCT04417062 2026-02-25

Olaparib With Ceralasertib in Recurrent Osteosarcoma

Dana-Farber Cancer Institute

Phase 2 Active not recruiting

Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡